



Probio-M9, a breast milk-originated probiotic, alleviates mastitis and enhances antibiotic efficacy: Insights into the gut-mammary axis.

Jie Yu^{1,2,3,4}, Weicheng Li^{1,2,3,4}, Ruibo Xu^{1,2,3,4,5}, Xiaoye Liu^{1,2,3,4},
Guangqi Gao^{1,2,3,4}, Lai-Yu Kwok^{1,2,3,4}, Yongfu Chen^{1,2,3,4}, Zhihong Sun^{1,2,3,4},
Wenjun Liu^{1,2,3,4}, Heping Zhang^{1,2,3,4*}

¹Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education;

²Key Laboratory of Dairy Products Processing, Ministry of Agriculture and Rural Affairs;

³Inner Mongolia Key Laboratory of Dairy Biotechnology and Engineering;

⁴Collaborative Innovative Center for Lactic Acid Bacteria and Fermented Dairy Products, Ministry of Education;

Inner Mongolia Agricultural University, Hohhot 010018, China


⁵School of Biological and Food Engineering, Chuzhou University, Chuzhou, 239000, China




Jie Yu#, Weicheng Li#, Ruibo Xu#, Xiaoye Liu#, Guangqi Gao, Lai-Yu Kwok, Yongfu Chen, Zhihong Sun, Wenjun Liu, Heping Zhang*. Probio-M9, a breast milk-originated probiotic, alleviates mastitis and enhances antibiotic efficacy: Insights into the gut-mammary axis. . *iMeta* 3: e224. <https://doi.org/10.1002/imt2.224>



Background





- ❑ Mastitis, a prevalent condition that affects nearly all lactating mammals. Mastitis leads to substantial economic losses worldwide due to the significant reduction in milk quality and quantity, directly impacting profitability and productivity.
- ❑ Probiotics may be an effective and safe strategy to treat mastitis.






Background



❑ Gut microbes can be transferred from mother to infant.



Highlights




- In this study, we evaluated the efficacy of the probiotic strain, *Lactocaseibacillus rhamnosus* Probio-M9, in treating mastitis by using a rat mammary model infected with *Staphylococcus aureus*. And the existence of a pathway of the gut-mammary translocation of Probio-M9.



Experimental Design I

Experiment I




❑ In experiment I, 72 female rats were randomly divided into six groups: positive control, blank control, antibiotic, antibiotic + Probio-M9, Probio-M9 treatment, and Probio-M9 prophylaxis.

❑ After delivery, all groups, except for the blank control group, underwent *S. aureus* infection via intra-mammary injection on day 0. Fecal samples were collected at two time points: day -26 and day 4. And the mammary glands of rats that were fed Probio-M9 were collected at day 4.





Results of Experiment I




- ❑ The Probio-M9 prophylactic group and the Probio-M9 treatment group showed little lymphocyte infiltration in the acinar cavity and stroma.
- ❑ Probio-M9 inhibits inflammation, Th1/Th2 balance returned to normal levels.
- ❑ Probio-M9 relieves mastitis and enhances antibiotic efficacy.



Results of Experiment I



(B)




□ Probio-M9 effectively relieved the lower alpha diversity caused by mastitis.

□ Probio-M9 increased the abundance of *Alistipes* sp. and decreased the abundance of *Bacteroides nordii* significantly.





Results of Experiment I




Administration of Probio-M9 significantly alleviated the alterations in the gene abundance of specific KEGG and CAZy.




Results of Experiment I



Probio-M9 treatment at 4d



Probio-M9 prophylaxis at 4d




Antibiotic + Probio-M9 at 4d

- ❑ Probio-M9 enhanced the interactions between microbiota and metabolic genes.
- ❑ All five cytokines (IFN- γ , IL-1 β , IL-6, IL-2, and IL-10) showed positive correlations with K19449, K23352, and *Ruminococcaceae* bacterium ($p < 0.05$, $R > 0.2$).
- ❑ Aforementioned species and metabolic pathways may play a key role in modulating immunity.



Experimental design II and results

Experiment II




- ❑ We conducted Experiment II, which closely resembled Experiment I but with two key modifications. Firstly, we excluded antibiotic treatment from the experimental design. Secondly, we included two additional groups: a non-mated (non-lactating) group and a group of rats not challenged with *S. aureus* but administered Probio-M9.
- ❑ Both *S. aureus*-induced mastitis and lactation were necessary prerequisites for bacterial translocation to occur, and bacterial translocation likely occurred through the lymphatic system.




Results of Experiment II

(A)



(B)




- 85 cultures were isolated exclusively from and MLN of lactating rats.
- There were only 20 SNPs across all isolates and no common mutations were found between the original Probio-M9 strain and the 85 cultures.
- These results indicate a high level of relatedness between these 85 isolates (collected from mammary gland and MLN of the 12 rats) and Probio-M9.



Summary

- ❑ Probio-M9 has the potential to alleviate mastitis and mitigate the adverse effects of antibiotic therapy.
- ❑ Through genomic-level analysis, we have identified instances of independent Probio-M9 translocation from the rat gut to the mammary gland, potentially involving the lymphatic system.
- ❑ Moreover, we have confirmed the requirement of lactation and the development of bacterial mastitis for bacterial translocation. While the precise mechanism of probiotic translocation remains unclear, our results suggest a selective rather than random process.


Jie Yu#, Weicheng Li#, Ruibo Xu#, Xiaoye Liu#, Guangqi Gao, Lai-Yu Kwok, Yongfu Chen, Zhihong Sun, Wenjun Liu, Heping Zhang*. Probio-M9, a breast milk-originated probiotic, alleviates mastitis and enhances antibiotic efficacy: Insights into the gut-mammary axis. . *iMeta* 3: e224. <https://doi.org/10.1002/imt2.224>



“***iMeta***” is a Wiley partner journal launched by iMeta Science Society in 2022, receiving its first impact factor (IF) of **23.7** in 2024, ranking 2/165 in the microbiology field. It aims to publish innovative and high-quality papers with broad and diverse audiences. Its scope is similar to *Nature Biotechnology*, *Nature Microbiology*, and *Cell Host & Microbe*. Its unique features include video abstract, bilingual publication, and social media dissemination, with more than 500,000 followers. It has published 200+ papers and been cited for 4000+ times, and has been indexed by [ESCI/WOS/JCR](#), [PubMed](#), [Google Scholar](#), and [Scopus](#).

“***iMetaOmics***” is a sister journal of “***iMeta***” launched in 2024, with a target IF>10, and its scope is similar to *Microbiome*, *ISME J*, *Nucleic Acids Research*, *Briefings in Bioinformatics*, *Bioinformatics*, etc. All contributes are welcome!

Society: <http://www.imeta.science>
Publisher: <https://wileyonlinelibrary.com/journal/imeta>

 office@imeta.science
imetaomics@imeta.science

 [iMetaScience](#)

Submission: <https://wiley.atyponrex.com/journal/IMT2>
<https://wiley.atyponrex.com/journal/IMO2>

 [Promotion Video](#)

 [iMetaScience](#)